ストックスクリーナーアプリを入手
30.32
3.06%
0.90
アフターアワーズ：
28.81
-1.51
-4.98%
前日終値:
$29.42
開ける：
$29.17
24時間の取引高:
684.37K
Relative Volume:
0.82
時価総額：
$4.44B
収益：
-
当期純損益:
$-272.55M
株価収益率:
-15.71
EPS:
-1.93
ネットキャッシュフロー:
$-243.55M
1週間 パフォーマンス:
+1.47%
1か月 パフォーマンス:
-0.62%
6か月 パフォーマンス:
+5.06%
1年 パフォーマンス:
-10.80%
1日の値動き範囲:
$28.45
$30.38
1週間の範囲:
$28.28
$30.38
52週間の値動き範囲:
$24.67
$45.58
Immunovant Inc Stock (IMVT) Company Profile
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-13 | アップグレード | UBS | Neutral → Buy |
| 2023-09-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 開始されました | BofA Securities | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-31 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2023-02-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2021-08-03 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-06-01 | ダウングレード | Stifel | Buy → Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-12 | 開始されました | Guggenheim | Buy |
| 2020-10-08 | 開始されました | Stifel | Buy |
| 2020-10-02 | 開始されました | Credit Suisse | Outperform |
| 2020-08-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-24 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Immunovant Inc (IMVT) 最新ニュース
Emerald Mutual Fund Advisers Trust Has $5.24 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Where are the Opportunities in (IMVT) - Stock Traders Daily
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Position Boosted by abrdn plc - MarketBeat
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - MarketBeat
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - The Manila Times
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - ForexTV.com
Immunovant's chief medical officer sells $94,171 in stock By Investing.com - Investing.com Canada
Immunovant CTO Jay Stout sells $80,912 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in Stock - MarketBeat
Immunovant CTO Jay Stout sells $80,912 in stock - Investing.com India
Immunovant's chief medical officer sells $94,171 in stock - Investing.com India
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 By Investing.com - Investing.com Australia
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 - Investing.com
Immunovant CFO Eva Renee Barnett sells $94,172 in stock By Investing.com - Investing.com Australia
Immunovant's chief medical officer William Macias sells $91,782 in stock - Investing.com India
Immunovant's chief legal officer sells $82,339 in stock By Investing.com - Investing.com Australia
Immunovant's chief legal officer sells $82,339 in stock - Investing.com India
Exchange Traded Concepts LLC Buys 9,438 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant CFO Eva Renee Barnett sells $94,172 in stock - Investing.com
Immunovant CEO Peter Salzmann sells $261,845 in shares By Investing.com - Investing.com Australia
Immunovant CEO Peter Salzmann sells $261,845 in shares - Investing.com
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $91,782.52 in Stock - MarketBeat
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
IMVT (Immunovant Inc) has impressive results - US Post News
Raymond James gives an Outperform recommendation for Immunovant Inc (IMVT) - Knox Daily
Analyzing Ratios: Immunovant Inc (IMVT)’s Financial Story Unveiled - The Dwinnex
Immunovant: Switching Lead Candidates Increases Risk (NASDAQ:IMVT) - Seeking Alpha
The Manufacturers Life Insurance Company Decreases Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant CEO sells over $131k in company stock By Investing.com - Investing.com Australia
Immunovant CFO sells over $150k in company stock By Investing.com - Investing.com Australia
Immunovant Inc [IMVT] stock for 104,976 USD was sold by Levine Mark S. - Knox Daily
Trend Tracker for (IMVT) - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) CEO Sells $131,837.60 in Stock - MarketBeat
Immunovant CEO sells over $131k in company stock - Investing.com India
Immunovant CFO sells over $150k in company stock - Investing.com
Noteworthy Friday Option Activity: IMVT, ALB, GCT - Nasdaq
Immunovant stock could attract strategic interest, says Raymond James By Investing.com - Investing.com UK
It would be worthwhile to take a closer look at Immunovant Inc (IMVT) - US Post News
Raymond James Reiterates "Outperform" Rating for Immunovant (NASDAQ:IMVT) - MarketBeat
Millennium Management LLC Sells 277,575 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant shares price target raised by Oppenheimer on positive trial data - Investing.com Canada
Oppenheimer Raises Immunovant (NASDAQ:IMVT) Price Target to $53.00 - MarketBeat
Analyzing Immunovant Inc (IMVT) After Recent Trading Activity - Knox Daily
Taking the lead: Immunovant Inc (IMVT) - SETE News
Dimensional Fund Advisors LP Reduces Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Financial Analysis: SpringWorks Therapeutics (NASDAQ:SWTX) vs. Immunovant (NASDAQ:IMVT) - Defense World
Immunovant Inc (IMVT) 財務データ
収益
当期純利益
現金流量
EPS
Immunovant Inc (IMVT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Geffner Michael | Chief Medical Officer |
Oct 23 '24 |
Sale |
29.53 |
3,189 |
94,171 |
134,971 |
| Stout Jay S | Chief Technology Officer |
Oct 23 '24 |
Sale |
29.53 |
2,740 |
80,912 |
142,186 |
| Salzmann Peter | Chief Executive Officer |
Oct 16 '24 |
Sale |
28.79 |
9,095 |
261,845 |
994,789 |
| Macias William L. | Chief Medical Officer |
Oct 16 '24 |
Sale |
28.79 |
3,188 |
91,783 |
365,144 |
| Levine Mark S. | Chief Legal Officer |
Oct 16 '24 |
Sale |
28.79 |
2,860 |
82,339 |
327,239 |
| Barnett Eva Renee | Chief Financial Officer |
Oct 16 '24 |
Sale |
28.79 |
3,271 |
94,172 |
335,343 |
| Barnett Eva Renee | Chief Financial Officer |
Oct 09 '24 |
Sale |
29.56 |
5,162 |
152,589 |
338,614 |
| Salzmann Peter | Chief Executive Officer |
Oct 09 '24 |
Sale |
29.56 |
4,460 |
131,838 |
1,003,884 |
| Levine Mark S. | Chief Legal Officer |
Aug 21 '24 |
Sale |
31.86 |
3,295 |
104,976 |
330,099 |
| Macias William L. | Chief Medical Officer |
Aug 21 '24 |
Sale |
31.86 |
3,027 |
96,437 |
368,332 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):